Hematology analyzers market seen reaching $7.19 billion by 2030

The hematology analyzers and reagents market is projected to rise from $5.26 billion in 2026 to $7.19 billion by 2030, driven by blood disorder diagnoses, automation and AI in labs. North America led the market in 2025, while the report points to stronger growth in emerging regions and point-of-care testing.

Why it matters: - Hematology analyzers and reagents support complete blood count testing and blood disorder diagnosis, making them central to routine clinical care. - Rising blood disorder incidence is expanding demand for faster, more accurate testing in hospitals, diagnostic labs and point-of-care settings. - The market outlook suggests a shift from slow near-term growth to stronger expansion later this decade as automation and AI spread.

What happened: - The Business Research Company released a report on the global hematology analyzers and reagents market on August 10, 2026. - The market is projected to move from $5.25 billion in 2025 to $5.26 billion in 2026, a 0.2% CAGR. - The same market is expected to reach $7.19 billion by 2030, reflecting an 8.1% CAGR. - Download a free sample of the report. - View the full market report.

The details: - The recent market increase has been supported by higher rates of anemia and other blood disorders, more hospital and diagnostic lab infrastructure, continued use of manual and semi-automated analyzers, rising demand for complete blood count testing and broader clinical diagnostic services. - Future growth is expected to come from AI-powered cell analysis, wider adoption of fully automated hematology analyzers, precision medicine and personalized diagnostics, expansion of diagnostic facilities in emerging regions and higher demand for reagents and consumables. - Key trends include high-throughput automated analyzers, earlier diagnosis of blood disorders, broader point-of-care hematology testing, reagent rental and consumable-based business models, and tighter quality control and standardization. - Hematology analyzers provide complete blood count data and a three-part differential count of white blood cells. - The instruments can detect small cell populations, which helps diagnose rare blood conditions. - Hematology analyzers also measure cell morphology for deeper patient insight. - In 2025, North America held the largest regional market share, followed by Western Europe. - The report also covers Asia-Pacific, Southeast Asia, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market that is still relatively mature in the near term, but could accelerate as labs shift toward automation and data-driven diagnostics. - The emphasis on emerging regions suggests growth will increasingly depend on expanding diagnostic access outside established markets. - Cancer Research UK reported in July 2024 that average annual new Hodgkin lymphoma cases in the UK are expected to rise from about 2,400 in 2023-2025 to about 2,900 in 2038-2040, underscoring the longer-term demand for blood testing.

What's next: - The Business Research Company says its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - Expanded adoption of automated analyzers, AI tools and point-of-care testing will likely shape the next phase of market growth. - The company also provided contact details for expert inquiries and social media channels, including LinkedIn, Facebook and X.

The bottom line: - The hematology analyzers and reagents market is moving from modest short-term growth to a more sizable expansion story by 2030, with automation, AI and rising blood disorder diagnoses doing most of the heavy lifting.